Fertility treatment and risk of non-gynecological cancer: a systematic review.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
fertility treatment, compared with untreated women or the general population
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Given the small number of studies and their heterogeneity, these findings should be interpreted cautiously. Further research is needed to clarify these associations.
[PURPOSE] Evidence on the relationship between fertility treatment and non-gynecologic cancers remains limited.
- 95% CI 1.07-1.54
- RR 1.28
APA
Kim S, Mo JA, et al. (2026). Fertility treatment and risk of non-gynecological cancer: a systematic review.. Archives of gynecology and obstetrics, 313(1), 5. https://doi.org/10.1007/s00404-025-08264-4
MLA
Kim S, et al.. "Fertility treatment and risk of non-gynecological cancer: a systematic review.." Archives of gynecology and obstetrics, vol. 313, no. 1, 2026, pp. 5.
PMID
41483166
Abstract
[PURPOSE] Evidence on the relationship between fertility treatment and non-gynecologic cancers remains limited. This study synthesizes available research on the association between fertility treatments and the risk of non-gynecologic cancers in women with infertility.
[METHODS] We systematically searched MEDLINE, EMBASE, and the Cochrane Library for studies involving women with infertility who received fertility treatment, compared with untreated women or the general population. Primary outcomes included the incidence of thyroid, colorectal, gastric, and lung cancers. Subgroup analyses were conducted by type of ovarian stimulation drug, in vitro fertilization (IVF) status, parity, length of follow-up, and choice of reference group.
[RESULTS] Fifteen studies met the inclusion criteria. Fertility treatment was positively, though imprecisely, associated with thyroid cancer (relative risk [RR] = 1.22; 95% confidence interval [CI]: 0.95-1.57). No increased risk of colorectal cancer was observed among treated women. Clomiphene citrate use was associated with a higher risk of thyroid cancer (RR = 1.28; 95% CI: 1.07-1.54) and a lower risk of colorectal cancer (RR = 0.79; 95% CI: 0.65-0.96).
[CONCLUSION] Fertility medications may increase the risk of thyroid cancer while potentially reducing the risk of colorectal cancer in women with infertility. Given the small number of studies and their heterogeneity, these findings should be interpreted cautiously. Further research is needed to clarify these associations.
[METHODS] We systematically searched MEDLINE, EMBASE, and the Cochrane Library for studies involving women with infertility who received fertility treatment, compared with untreated women or the general population. Primary outcomes included the incidence of thyroid, colorectal, gastric, and lung cancers. Subgroup analyses were conducted by type of ovarian stimulation drug, in vitro fertilization (IVF) status, parity, length of follow-up, and choice of reference group.
[RESULTS] Fifteen studies met the inclusion criteria. Fertility treatment was positively, though imprecisely, associated with thyroid cancer (relative risk [RR] = 1.22; 95% confidence interval [CI]: 0.95-1.57). No increased risk of colorectal cancer was observed among treated women. Clomiphene citrate use was associated with a higher risk of thyroid cancer (RR = 1.28; 95% CI: 1.07-1.54) and a lower risk of colorectal cancer (RR = 0.79; 95% CI: 0.65-0.96).
[CONCLUSION] Fertility medications may increase the risk of thyroid cancer while potentially reducing the risk of colorectal cancer in women with infertility. Given the small number of studies and their heterogeneity, these findings should be interpreted cautiously. Further research is needed to clarify these associations.
MeSH Terms
Humans; Female; Thyroid Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Stomach Neoplasms; Fertility Agents, Female; Infertility, Female; Fertilization in Vitro; Ovulation Induction; Clomiphene; Risk Factors
같은 제1저자의 인용 많은 논문 (5)
- Size matters: Establishing a cut-off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines.
- Immunoresistant to immunosensitive - Histotripsy's unique potential to overcome resistance.
- Secondary Cancer Risk in Breast Cancer with and without Radiotherapy: The Observational Health Data Sciences and Informatics (OHDSI) Cohort Study.
- Robust Multimodal Deep Learning for Lymphoma Subtype Classification Using F-FDG PET Maximum Intensity Projection Images and Clinical Data: A Multi-Center Study.
- Mediating roles of cancer stigma and resilience in the relationship between type D personality and quality of life among patients with breast cancer undergoing chemotherapy.